<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00267033</url>
  </required_header>
  <id_info>
    <org_study_id>P040426</org_study_id>
    <secondary_id>AOM04013</secondary_id>
    <nct_id>NCT00267033</nct_id>
  </id_info>
  <brief_title>Evaluation of Vertebroplasty Associated With Radiotherapy for Spine Metastases (EVAR)</brief_title>
  <official_title>Randomized Trial of Vertebroplasty and Radiotherapy Versus Radiotherapy Alone for Osseous Spine Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized phase III study of palliative external beam radiotherapy (RTOG 97-14) has shown
      that 8 Gy in a single fraction is very effective in providing pain relief, with complete or
      partial improvement in pain seen in 66% of patients with bone metastases. Percutaneous
      vertebroplasty (PV) is a technique designed to consolidate pathologic vertebral bodies
      through the injection of orthopaedic cement under fluoroscopic guidance. Consolidation
      provides rapid pain relief to painful vertebral body lesions secondary to osteoporosis,
      haemangiomas, myeloma and metastatic diseases, with complete or partial improvement in pain
      seen in 70-85% of patients. To date, no randomized trial has tested the association of
      vertebroplasty and radiotherapy to enhance pain relief for patients with painful osseous
      spine metastases.

      A randomized trial has been designed to determine whether vertebroplasty and radiotherapy (8
      Gy in a single fraction) provide enhancement pain and narcotic relief compared to
      radiotherapy alone for patients with painful osseous spine metastases
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with 1 to 4 painful osseous spine metastases are randomized to 1 of 2 treatment
      arms:

        -  Arm 1: 8 Gy in a single fraction

        -  Arm 2: 8 Gy in a single fraction followed by vertebroplasty of the vertebral bodies,
           within 14 days after radiotherapy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of pain relief with the Brief Pain Index (BPI), by a blind arm trial algologist, 3 months after radiotherapy.</measure>
    <time_frame>3 months after radiotherapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response will be scored as complete (no pain), partial (improvement of &lt; 2 points in BPI), stable (+/- 1 point change in BPI) or progressive (&gt; 2 point worsening of BPI).</measure>
    <time_frame>during the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete and partial responses will be considered treatment success, and stable and progressive responses will be considered treatment failures</measure>
    <time_frame>during the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pain relief one month after radiotherapy</measure>
    <time_frame>one month after radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BPI-SF and EORTC QLQ-C30 will be used to assess general cancer quality of life.</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of vertebral pathologic fracture will be registered.</measure>
    <time_frame>one month after radiotherapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">186</enrollment>
  <condition>Osseous Spine Metastases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>injection of orthopaedic cement into vertebral bodies</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>injection of orthopaedic cement into vertebral bodies</intervention_name>
    <description>injection of orthopaedic cement into vertebral bodies</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Osseous spine metastases from squamous cell carcinoma or adenocarcinoma

          -  One to four painful metastases located between the second cervical vertebra and the
             fifth lumbar vertebra

          -  Moderate to severe pain

          -  No spinal cord compression

          -  Karnofsky performance status &gt; 40

        Exclusion Criteria:

          -  Previous radiotherapy or surgery

          -  Vertebral fracture or any other formal indication of stabilization of the rachis by
             surgery or vertebroplasty

          -  Spinal cord compression

          -  Known anomaly of the haemostasis, or needed anticoagulant treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jean-Marc SIMON, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Pitié-Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M 3rd, Suh JH, Demas WF, Movsas B, Petersen IA, Konski AA, Cleeland CS, Janjan NA, DeSilvio M. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005 Jun 1;97(11):798-804.</citation>
    <PMID>15928300</PMID>
  </reference>
  <reference>
    <citation>Weill A, Chiras J, Simon JM, Rose M, Sola-Martinez T, Enkaoua E. Spinal metastases: indications for and results of percutaneous injection of acrylic surgical cement. Radiology. 1996 Apr;199(1):241-7.</citation>
    <PMID>8633152</PMID>
  </reference>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2005</study_first_submitted>
  <study_first_submitted_qc>December 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2005</study_first_posted>
  <last_update_submitted>December 1, 2008</last_update_submitted>
  <last_update_submitted_qc>December 1, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2008</last_update_posted>
  <responsible_party>
    <name_title>Myriem CARRIER</name_title>
    <organization>Department Clinical Research of Developpement</organization>
  </responsible_party>
  <keyword>Neoplasm Metastasis</keyword>
  <keyword>Bone Neoplasms</keyword>
  <keyword>Pain</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Vertebroplasty</keyword>
  <keyword>Combined modality therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

